Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death

Cancer Biology and Therapy

Volumn 11, Issue 1, 2011, Pages 4-13

  Ametller, Elisabet ^a   García Recio, Susana ^a   Pastor Arroyo, Eva María ^a   Callejo, Gerard ^a   Carbó, Neus ^a   Gascón, Pedro ^a   Almendro, Vanessa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

catenin; Chemoresistance; EGFR; MMP7; Oxaliplatin

Indexed keywords

BETA CATENIN; MATRILYSIN; MESSENGER RNA; OXALIPLATIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PEA3; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; ENZYME REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HCT116 CELLS; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 7; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION;

EID: 78751558489     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.1.13672     Document Type: Article

References (21)

1. Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, Matrisian LM. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 1994; 269:2032-40.
2. Kheradmand F, Werner E, Tremble P, Symons M, Werb Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998; 280:898-902.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
4. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42:317-25.
5. Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC, Liu JF, et al. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer 2007; 97:334-44.
6. Almendro V, Ametller E, Garcia-Recio S, Collazo O, Casas I, Auge JM, et al. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One 2009; 4:4728.
7. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003; 201:528-34.
8. Kurokawa S, Arimura Y, Yamamoto H, Adachi Y, Endo T, Sato T, et al. Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut 2005; 54:1751-8.
9. Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7 increases resistance to Fasmediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006; 27:1113-20.
10. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61:577-81.
11. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of betacatenin with the transcription factor LEF-1. Nature 1996; 382:638-42.
12. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999; 18:2883-91.
13. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. betacatenin regulates the expression of the matrix metalloproteinase- 7 in human colorectal cancer. Am J Pathol 1999; 155:1033-8.
14. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002; 122:60-71.
15. Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA, et al. The PEA3 subfamily of Ets transcription factors synergizes with betacatenin- LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001; 21:1370-83.
16. Lynch CC, Crawford HC, Matrisian LM, McDonnell S. Epidermal growth factor upregulates matrix metalloproteinase- 7 expression through activation of PEA3 transcription factors. Int J Oncol 2004; 24:1565-72.
17. Ametller E, Garcia-Recio S, Costamagna D, Mayordomo C, Fernandez-Nogueira P, Carbo N, et al. Tumor promoting effects of CD95 signaling in chemoresistant cells. Mol Cancer 9:161.
18. Cimbora-Zovko T, Ambriovic-Ristov A, Loncarek J, Osmak M. Altered cell-cell adhesion in cisplatinresistant human carcinoma cells: a link between betacatenin/ plakoglobin ratio and cisplatin resistance. Eur J Pharmacol 2007; 558:27-36.
19. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006; 281:17751-7.
20. Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003; 201:250-9.
21. Kim BM, Mao J, Taketo MM, Shivdasani RA. Phases of canonical Wnt signaling during the development of mouse intestinal epithelium. Gastroenterology 2007; 133:529-38.